An allogeneic stem cell transplant is a procedure in which stem cells from a healthy donor replace a patient’s diseased bone marrow. It’s one of the most powerful treatments available for blood cancers and other serious blood disorders, and it works through two distinct mechanisms: rebuilding the body’s ability to produce healthy blood cells, and harnessing the donor’s immune system to attack any remaining disease. Around 49% of patients who received this transplant between 2013 and 2018 survived at least five years, up from 35% in the early 2000s.
How It Differs From an Autologous Transplant
The word “allogeneic” simply means the cells come from someone else. In an autologous transplant, your own stem cells are collected, stored, and returned to you after high-dose chemotherapy. That approach avoids certain immune complications, but it has a significant limitation: the transplanted cells can’t fight leftover cancer because they’re your own immune system. There’s also a risk that cancer cells collected alongside your stem cells get reinfused.
An allogeneic transplant uses stem cells from a donor, which means two major advantages. First, the donor’s cells are cancer-free. Second, the donor’s immune cells can recognize and destroy residual cancer cells in your body, a phenomenon called the graft-versus-tumor effect. The trade-off is a higher risk of immune complications, since the donor’s cells may also attack your healthy tissues.
Why It Works: More Than Just New Marrow
The procedure was originally designed as straightforward organ replacement. Destroy the diseased bone marrow, then rebuild it with healthy donor cells. But researchers quickly discovered that replacing marrow was only half the story. The donor’s immune cells, particularly a type of white blood cell called T cells, actively hunt down and eliminate remaining cancer cells. These donor T cells recognize small protein differences between the donor’s body and the recipient’s, and they target cells carrying those differences. Because the recipient’s blood-forming system (including any leukemia cells hiding within it) is the most sensitive target, this immune response can be remarkably effective at clearing residual disease.
This built-in immune attack is the reason allogeneic transplants remain the treatment of choice for many aggressive blood cancers, even as newer therapies emerge. It’s essentially a form of immunotherapy delivered alongside the transplant itself.
Conditions Treated
Allogeneic transplants are most commonly used for leukemias (acute and chronic), lymphomas, myelodysplastic syndromes, and other bone marrow disorders like aplastic anemia. In chronic myeloid leukemia specifically, five-year survival improved from 46% to 66% between the early 2000s and the 2013 to 2018 period. For acute lymphoblastic leukemia, that improvement went from 41% to 59% over the same timeframe.
Finding a Matched Donor
Your body has 12 unique HLA markers, proteins on the surface of your cells that your immune system uses to distinguish “self” from “foreign.” These markers create millions of possible combinations, which is why finding a well-matched donor can be challenging. A full match means the donor shares all of your HLA markers. A partial match shares most but not all. A haploidentical (or “haplo”) match shares exactly half, which is common between a parent and child.
Siblings have roughly a 25% chance of being a full match. When no matched family member is available, doctors search registries like the National Marrow Donor Program for unrelated donors. The closer the HLA match, the lower the risk of serious immune complications after transplant.
Where Donor Cells Come From
Stem cells can be harvested from three sources: peripheral blood (collected from the donor’s bloodstream after medication stimulates stem cell release), bone marrow (drawn directly from the hip bone), or umbilical cord blood (collected at birth and banked for future use). Each source carries different trade-offs.
Peripheral blood is the most commonly used source for adult patients because engraftment, the point at which donor cells begin producing new blood cells, happens faster. Bone marrow transplants take longer to engraft but carry meaningfully lower rates of chronic graft-versus-host disease. A Cochrane review found that bone marrow reduced the risk of extensive chronic GVHD by about 31% and overall chronic GVHD by about 28% compared to peripheral blood. Bone marrow may also reduce the risk of severe acute GVHD, though the evidence on that point is less definitive. The choice between sources depends on the disease being treated, the donor’s preference, and how the transplant team weighs speed of recovery against long-term immune complications.
The Conditioning Phase
Before you receive donor cells, your existing bone marrow needs to be suppressed or destroyed. This “conditioning” phase uses chemotherapy, total body irradiation, or both. It serves two purposes: making room for the donor’s stem cells and weakening your immune system enough that it won’t reject them.
Conditioning comes in different intensities. Full-intensity (myeloablative) conditioning completely wipes out your bone marrow. Without a transplant afterward, your body could not recover on its own. This approach is standard for younger, healthier patients who can tolerate the side effects. Reduced-intensity conditioning uses lower doses that rely more heavily on the donor’s immune cells to take over, rather than completely destroying existing marrow first. This option opened the door for older patients and those with other health conditions who wouldn’t survive full-intensity treatment.
Engraftment and Early Recovery
The transplant itself is surprisingly undramatic. Donor stem cells are infused through an IV, much like a blood transfusion. The cells find their way to your bone marrow on their own and begin multiplying. The waiting period that follows is the most vulnerable phase. Until the donor cells engraft and start producing white blood cells, you have essentially no functioning immune system.
Neutrophil recovery, the point at which your infection-fighting white blood cells reach a safe level, typically happens around 12 to 14 days after transplant when peripheral blood is the stem cell source. During this window you’ll remain hospitalized or closely monitored, often in a protective isolation environment. Platelet and red blood cell recovery generally take longer, requiring transfusion support in the interim. Most patients spend several weeks in the hospital, and full immune recovery can take months to over a year.
Patients who survive the first year have substantially better long-term odds. Five-year survival for those alive at one year improved from 64% in the early 2000s to 73% in the most recent era studied, reflecting better supportive care and infection management.
Graft-versus-Host Disease
The same immune mechanism that fights leftover cancer can also turn against healthy tissues. Graft-versus-host disease (GVHD) occurs when the donor’s immune cells attack the recipient’s organs, and it’s the most significant complication unique to allogeneic transplants. About 35% of patients develop acute GVHD severe enough to require treatment, with an additional 6% developing a late-onset form.
Acute GVHD most commonly affects the skin (rashes), the gastrointestinal tract (nausea, diarrhea, abdominal pain), and the liver. Late-onset acute GVHD tends to hit the lower gastrointestinal tract harder than the classic form. Chronic GVHD can develop months after transplant and may affect a wider range of organs, sometimes resembling autoimmune conditions with dry eyes, skin changes, or joint stiffness. It can range from mild and manageable to severe and life-altering.
Preventing and managing GVHD is a balancing act. Immunosuppressive medications tamp down the donor immune response, but too much suppression can blunt the graft-versus-tumor effect and leave you vulnerable to infections. Transplant teams adjust this balance continuously based on how each patient responds.
Other Risks to Know About
Beyond GVHD, infection is a major concern throughout recovery. Your rebuilt immune system takes time to mature, and previously dormant infections (like certain viruses your body had been keeping in check) can reactivate when your immune defenses are suppressed. Graft failure, where the donor cells don’t successfully take hold, is possible though uncommon. There’s also a small risk of infections transmitted from the donor, despite thorough screening.
The intensity of conditioning treatment brings its own side effects: fatigue, nausea, mouth sores, organ stress, and temporary or permanent infertility. These vary significantly depending on whether you receive full-intensity or reduced-intensity conditioning.